[Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
We report two cases of fulminant hepatitis induced by antitubercular drugs. The mechanism is both immunoallergic and toxic. The fatal case appears in patient with acquired immunodeficiency syndrome. Liver tests must be realized during antitubercular treatment, that is difficult in sub-Saharan Africa.
Mbaye
P S
PS
Services Médicaux, Hôpital Principal de Dakar, Senegal.
Talarmin
F
F
Sane
M
M
Eladari
D
D
Klotz
F
F
D000328:Adult; D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004359:Drug Therapy, Combination / Q000009:adverse effects* / Q000627:therapeutic use; D004977:Ethambutol / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects* / Q000627:therapeutic use; D008111:Liver Function Tests; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D014391:Tuberculosis, Miliary / Q000150:complications / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin
Hépatite fulminante au cours d'un traitement par les antituberculeux (à propos de deux cas).